All In Biotech

Drug Trial Radar · NCT00126412

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma

Last checked: Nov 20, 2026Latest source record: May 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Aug 2, 2005

Primary completion

Sep 27, 2006

Study completion Sep 27, 2006

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
First posted
Aug 4, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.

Conditions

  • Pheochromocytoma
  • Neuroblastoma

Interventions

  • 123I-mIBG (meta-iodobenzylguanidine)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GE Healthcare

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.